Research programme: neuregulins - Minerva Neurosciences

Drug Profile

Research programme: neuregulins - Minerva Neurosciences

Alternative Names: CNS growth factors - Mind-NRG; MIN-301; NRG-101

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProteoSys
  • Developer Minerva Neurosciences; ProteoSys
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Neuregulins; Neuroprotectants; Recombinant proteins
  • Mechanism of Action ERBB 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; CNS disorders; Parkinson's disease; Schizophrenia

Most Recent Events

  • 12 Mar 2018 Minerva Neurosciences plans a phase I trial for Parkinson's disease
  • 09 Aug 2017 MIN 301 is still in preclinical trials for Parkinson's disease in Switzerland
  • 04 Aug 2017 Minerva Neurosciences plans to file an IND application for MIN 301 in Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top